Terms: = Leukemia AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
32 results:
1. A GPX4 non-enzymatic domain and mdm2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract] [Full Text] [Related]
2. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
3. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic Silencing of
Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
[TBL] [Abstract] [Full Text] [Related]
5. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract] [Full Text] [Related]
6. Novel Targeted Therapeutics in Acute Myeloid leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract] [Full Text] [Related]
7. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract] [Full Text] [Related]
8. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
Abo Elwafa R; Abd Elrahman A; Ghallab O
Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
[TBL] [Abstract] [Full Text] [Related]
9. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.
Montesinos P; Beckermann BM; Catalani O; Esteve J; Gamel K; Konopleva MY; Martinelli G; Monnet A; Papayannidis C; Park A; Récher C; Rodríguez-Veiga R; Röllig C; Vey N; Wei AH; Yoon SS; Fenaux P
Future Oncol; 2020 May; 16(13):807-815. PubMed ID: 32167393
[TBL] [Abstract] [Full Text] [Related]
10. mdm2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract] [Full Text] [Related]
11. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract] [Full Text] [Related]
12. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
Hernández-Sánchez M; Rodríguez-Vicente AE; Hernández JÁ; Lumbreras E; Sarasquete ME; Martín AÁ; Benito R; Vicente-Gutiérrez C; Robledo C; Heras Nde L; Rodríguez JN; Alcoceba M; Coca AG; Aguilar C; González M; Hernández-Rivas JM
Leuk Res; 2016 Jul; 46():30-6. PubMed ID: 27111859
[TBL] [Abstract] [Full Text] [Related]
13. Association of mdm2 polymorphism with risk and prognosis of leukemia: a meta-analysis.
He X; Chen P; Yang K; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
Acta Haematol; 2015; 133(4):365-371. PubMed ID: 25790771
[TBL] [Abstract] [Full Text] [Related]
14. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/mdm2 in colorectal cancers.
Yu H; Yue X; Zhao Y; Li X; Wu L; Zhang C; Liu Z; Lin K; Xu-Monette ZY; Young KH; Liu J; Shen Z; Feng Z; Hu W
Nat Commun; 2014 Oct; 5():5218. PubMed ID: 25323535
[TBL] [Abstract] [Full Text] [Related]
15. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
16. TP53 mutations and mdm2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract] [Full Text] [Related]
17. mdm2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
Benner A; Mansouri L; Rossi D; Majid A; Willander K; Parker A; Bond G; Pavlova S; Nückel H; Merkel O; Ghia P; Montserrat E; Kaderi MA; Rosenquist R; Gaidano G; Dyer MJ; Söderkvist P; Linderholm M; Oscier D; Tvaruzkova Z; Pospisilova S; Dührsen U; Greil R; Döhner H; Stilgenbauer S; Zenz T;
Haematologica; 2014 Aug; 99(8):1285-91. PubMed ID: 25082786
[TBL] [Abstract] [Full Text] [Related]
18. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Cirstea D; Hideshima T; Santo L; Eda H; Mishima Y; Nemani N; Hu Y; Mimura N; Cottini F; Gorgun G; Ohguchi H; Suzuki R; Loferer H; Munshi NC; Anderson KC; Raje N
Leukemia; 2013 Dec; 27(12):2366-75. PubMed ID: 23807770
[TBL] [Abstract] [Full Text] [Related]
19. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract] [Full Text] [Related]
20. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
Kojima K; McQueen T; Chen Y; Jacamo R; Konopleva M; Shinojima N; Shpall E; Huang X; Andreeff M
Blood; 2011 Oct; 118(16):4431-9. PubMed ID: 21868571
[TBL] [Abstract] [Full Text] [Related]
[Next]
